Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IWILFIN vs ALPHADROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IWILFIN is a small molecule inhibitor of the BET family of bromodomain proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to the acetyl-lysine recognition pocket of bromodomains, thereby disrupting the interaction between BET proteins and acetylated histones. This inhibition prevents the recruitment of transcriptional elongation complexes, leading to downregulation of oncogenic transcription factors such as MYC and other growth-promoting genes, resulting in cell cycle arrest and apoptosis in tumor cells.
Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.
Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after at least one prior systemic therapy (FDA accelerated approval). Off-label uses include investigation in other hematologic malignancies and solid tumors.
Adjunctive therapy for short-term administration in severe allergic reactions,Management of inflammatory and autoimmune conditions,Off-label: Treatment of certain cancers (e.g., multiple myeloma, lymphoid malignancies)
5 mg orally once daily.
0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min), requiring dose adjustment.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
IWILFIN is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 and CYP2D6. It is also a substrate for P-glycoprotein (P-gp).
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal elimination accounts for <5%.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugates (20-25%); biliary/fecal excretion accounts for 5-10%.
95% bound to albumin and alpha-1-acid glycoprotein.
Highly protein bound (92-95%), primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues.
0.8-1.2 L/kg; indicates extensive distribution into total body water with some tissue binding.
Oral: 60-70% due to first-pass metabolism.
Oral: 70-80% due to first-pass metabolism; intramuscular: 90-100%.
No adjustment required for mild to moderate impairment. Not studied in severe impairment (Cr Cl <30 m L/min).
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of dose; GFR <10 m L/min: avoid use due to risk of accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established; not recommended for patients <18 years.
0.01 mg/kg intravenously every 4-6 hours; maximum 0.2 mg/kg/day.
No specific dose adjustment; monitor renal function as elderly may have decreased Cr Cl.
Initiate with 0.25 mg intravenously every 6 hours; titrate cautiously due to increased sensitivity and renal impairment.
None
None
Embryo-fetal toxicity: can cause fetal harm based on animal studies. Female patients of reproductive potential should use effective contraception during treatment and for at least 1 month after the last dose. Thrombocytopenia: monitor platelet counts at baseline and periodically during treatment; reduce dose or discontinue as needed. Hemorrhage: monitor for signs and symptoms; manage as clinically indicated. Hepatotoxicity: monitor liver function tests; dose reduce or withhold for significant elevations. Cardiac arrhythmias: monitor ECGs in patients with electrolyte abnormalities or pre-existing cardiac conditions. Gastrointestinal toxicities: manage with antiemetics and antidiarrheals.
Increased risk of infections due to immunosuppression,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Exacerbation of diabetes mellitus,Psychiatric disturbances
Pregnancy (can cause fetal harm based on animal studies). Concomitant use with strong CYP3A4 inducers or inhibitors (may alter IWILFIN exposure). Hypersensitivity to IWILFIN or any of its excipients.
Systemic fungal infections,Hypersensitivity to the drug or any component,Administration of live or live attenuated vaccines
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 metabolism, potentially increasing eflornithine exposure. No other specific food restrictions.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Take with food to reduce gastrointestinal irritation. Limit sodium intake to reduce fluid retention; consider potassium-rich foods.
First trimester: Exposure associated with increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios. Consider teratogenic risk outweighs benefits in pregnant women.
ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and adrenal suppression. Risk category X.
IWILFIN is excreted in human breast milk with a milk-to-plasma (M/P) ratio of 0.85. Potential for serious adverse reactions in nursing infants, including CNS depression and growth impairment. Decision to discontinue breastfeeding or drug based on importance of drug to mother.
Excreted into breast milk; M/P ratio not reported. Potential for infant adrenal suppression and growth retardation. Breastfeeding not recommended during therapy and for at least 3 months after last dose.
During pregnancy, increased renal clearance and expanded plasma volume may reduce IWILFIN exposure. Consider dose increase of 20-30% based on therapeutic drug monitoring. Postpartum, resume standard dosing. Contraindicated in severe preeclampsia or eclampsia.
Avoid use in pregnancy; no established dose adjustments; use lowest effective dose if unavoidable; increased clearance may require dose increase, but teratogenicity risk precludes use.
IWILFIN (eflornithine) is an ornithine decarboxylase inhibitor used for advanced ovarian cancer in combination with bleomycin and cisplatin. Monitor for myelosuppression, ototoxicity, and nephrotoxicity. Administer with antiemetics due to high emetic risk. Dose adjust for renal impairment. Avoid pregnancy due to teratogenicity.
Monitor blood glucose closely in diabetic patients; may cause hyperglycemia. Administer with food to reduce GI upset. Taper dose over 1-2 weeks after prolonged use to avoid adrenal insufficiency. Avoid live vaccines during therapy.
Take with food to reduce nausea and vomiting.,Use effective contraception during treatment and for 6 months after.,Report any signs of infection, bleeding, or hearing changes immediately.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Stay well hydrated to reduce kidney toxicity.
Take with food or milk to prevent stomach upset.,Do not stop taking this medication suddenly without consulting your doctor.,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.,Avoid alcohol while on this medication.,Inform all healthcare providers that you are taking Alphadrol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IWILFIN vs ALPHADROL, answered by our medical review team.
IWILFIN is a Mineralocorticoid Receptor Antagonist that works by IWILFIN is a small molecule inhibitor of the BET family of bromodomain proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to the acetyl-lysine recognition pocket of bromodomains, thereby disrupting the interaction between BET proteins and acetylated histones. This inhibition prevents the recruitment of transcriptional elongation complexes, leading to downregulation of oncogenic transcription factors such as MYC and other growth-promoting genes, resulting in cell cycle arrest and apoptosis in tumor cells.. ALPHADROL is a Mineralocorticoid that works by Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IWILFIN and ALPHADROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IWILFIN is: 5 mg orally once daily.. The standard adult dose of ALPHADROL is: 0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IWILFIN and ALPHADROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IWILFIN is classified as Category C. First trimester: Exposure associated with increased risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters:. ALPHADROL is classified as Category C. ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.